e-learning
resources
Stockholm 2007
Monday 17.09.2007
Therapy of thoracic malignancies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Zoledronic acid limits experimental malignant pleural effusion
G. T. Stathopoulos, C. Moschos, A. Kollintza, I. Psallidas, H. Loutrari, S. Magkouta, H. Petrocheilou, P. Theodoropoulou, S. A. Papiris, C. Roussos, I. Kalomenidis (Athens, Greece)
Source:
Annual Congress 2007 - Therapy of thoracic malignancies
Session:
Therapy of thoracic malignancies
Session type:
Thematic Poster Session
Number:
2552
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. T. Stathopoulos, C. Moschos, A. Kollintza, I. Psallidas, H. Loutrari, S. Magkouta, H. Petrocheilou, P. Theodoropoulou, S. A. Papiris, C. Roussos, I. Kalomenidis (Athens, Greece). Zoledronic acid limits experimental malignant pleural effusion. Eur Respir J 2007; 30: Suppl. 51, 2552
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Cytological diagnosis of malignant mesothelioma – improvement by additional determination of hyaluronic acid in pleural effusions
Source: Eur Respir J 2006; 28: Suppl. 50, 783s
Year: 2006
Hyaluronic acid levels are increased in parapneumonic pleural effusions
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Diagnostic efficiency of pleural fluid lipid-bound sialic acid level in malignant pleural effusions
Source: Eur Respir J 2002; 20: Suppl. 38, 439s
Year: 2002
Tranexamic acid versus bleomycin pleurodesis for malignant pleural effusion via tube drainage
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010
Pleurodesis in the treatment of malignant pleural effusion
Source: Eur Respir J 2004; 24: Suppl. 48, 628s
Year: 2004
All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice
Source: Eur Respir J 2009; 34: 1159-1167
Year: 2009
Pleurodesis for malignant pleural effusion
Source: ERS Course 2016 - Skills course on medical thoracoscopy
Year: 2016
Pleurodesis for malignant pleural effusion
Source: School Course 2014 - Medical Thoracoscopy
Year: 2014
Videothoracoscopy in the treatment of malignant pleural effusions
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Transudative malignant pleural effusions
Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice?
Year: 2019
Management of malignant pleural effusion
Source: Eur Respir J 2001; 18: Suppl. 33, 397s
Year: 2001
The role of pleural aspirate acid fast bacilli in pleural effusion of unknown cause
Source: Eur Respir J 2005; 26: Suppl. 49, 448s
Year: 2005
Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion
Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Year: 2012
Pleurodesis for malignant pleural effusion: which compound?
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013
Pleurodesis for malignant pleural effusion: which compound?
Source: Hands-on Course 2012 - Medical Thoracoscopy
Year: 2012
Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Year: 2019
Separating malignant from nonmalignant pleural effusion on the basis of
P
O
2
in pleural effusion
Source: Eur Respir J 2003; 22: Suppl. 45, 541s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept